6 completed, 6 terminated, 4 active not recruiting, 1 recruiting. 15 Phase 2, 8 Phase 1, 1 Not applicable.
Follow Criterium, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer Fruquintinib+ Lonsurf (trifluridine and tipiracil), Fruquintinib - Colorectal Cancer | Phase 2 | Recruiting | Criterium, Inc. | 120 | 2025-10-27 | 2026-10-15 |
| Tucatinib+Trastuzumab+Eribulin in HER2+ MBC Tucatinib, Eribulin, Trastuzumab - Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer | Phase 2 | Active not recruiting | Criterium, Inc. | 17 | 2024-01-30 | 2026-07-10 |
| Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. Alpelisib, Tucatinib, Fulvestrant - HER2-positive Metastatic Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Criterium, Inc. | 40 | 2022-08-25 | 2026-03-16 |
| Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer Evorpacept (ALX148), Cetuximab, Pembrolizumab - Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | Terminated | University of Colorado, Denver | 19 | 2022-07-28 | 2026-09-03 |
| A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis AMG 510, MVASI - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Withdrawn | Criterium, Inc. | 2022-06-15 | 2023-10-18 | |
| CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 2 | 2022-05-25 | 2023-10-18 |
| Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer Abemaciclib, Elacestrant - Breast Cancer | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 5 | 2022-04-21 | 2026-03-31 |
| Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer Cabozantinib, Nivolumab - Colorectal Adenocarcinoma, Colon Cancer | Phase 2 | Active not recruiting | University of Colorado, Denver | 48 | 2021-06-23 | 2026-03-31 |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) Palbociclib, Fulvestrant, Adjuvant Therapy - Breast Cancer | Phase 2 | Active not recruiting | Criterium, Inc. | 70 | 2021-02-09 | 2026-10-15 |
| FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer Oxaliplatin - Colorectal Cancer Metastatic | Phase 2 | Unknown | Criterium, Inc. | 27 | 2019-12-02 | 2023-07-27 |
| Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases Non-Small Cell Lung Cancer | Completed | University of Colorado, Denver | 18 | 2018-02-22 | 2025-03-25 | |
| Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Tucatinib in Combination with Palbociclib and Letrozole - Breast Cancer | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 42 | 2017-11-27 | 2023-11-13 |
| Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors brigatinib - Non-Small Cell Lung Cancer | Phase 2 | Terminated | Criterium, Inc. | 32 | 2017-03-09 | 2023-01-26 |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Nab paclitaxel, Gemcitabine - Pancreatic Cancer, Pancreatic Adenocarcinoma | Phase 2 | Completed | Academic Thoracic Oncology Medical Investigators Consortium | 48 | 2016-12-30 | 2025-07-01 |
| Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies ceritinib - Colorectal Adenocarcinoma, Cholangiocarcinoma | Phase 2 | Terminated | Criterium, Inc. | 4 | 2015-12-01 | 2018-04-02 |
| A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis Carfilzomib, Dexamethasone - Amyloidosis, Systemic Light Chain Amyloidosis | Phase 1 | Completed | Criterium, Inc. | 32 | 2013-02-01 | 2017-10-18 |
| A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma Carfilzomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 1 | Completed | Criterium, Inc. | 29 | 2013-01-01 | 2017-10-18 |
| Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns P6 Low Adherent Dressing, Standard of Care (SOC) - Burns, Skin Burn Requiring Skin Graft | Not applicable | Completed | Milliken Healthcare Products, LLC | 80 | 2012-10-01 | 2017-10-02 |
| A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Criterium, Inc. | 136 | 2011-11-01 | 2022-08-01 |
Breast Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Multiple Myeloma (2) · Adenocarcinoma Of Esophagus (1) · Amyloidosis (1) · Burns (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1)
Calcium Dobesilate (3) · Dexamethasone (3) · carfilzomib (3) · tucatinib (3) · Fulvestrant (2) · Standard of Care (2) · palbociclib (2) · ALX148 (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Bevacizumab (1) · Cetuximab (1) · Chemotherapy, Adjuvant (1) · Cyclophosphamide (1) · Gemcitabine (1)
United States (19) · Canada (1)
Brian GM Durie, MD (3) · Jatin Shah, MD (2) · Wells Messersmith, MD (2) · Adam Cohen, MD (1) · Alexis Leal, MD (1) · Bruce Cairns, MD (1) · Camidge Ross, MD (1) · Christopher Lieu, MD (1) · David R Camidge, MD, PhD (1) · Elena Shagisultanova, MD (1) · Elena Shagisultanova, MD, PhD (1) · Hank Kaplan, MD (1) · Howard Hochster, MD (1) · Lajos Pusztai, MD (1) · Peter Kabos, MD (1)
PMID 26384354, PMID 33039599, PMID 34728571, PMID 36101520, PMID 37363965, PMID 40972532, PMID 41171165, PMID 42610703
P30CA046934 (1)